Agios Pharmaceuticals is a biopharmaceutical company focused on areas of hematologic malignancies, solid tumors and rare genetic diseases. Co.'s product, TIBSOVO® (ivosidenib) is for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase (IDH) 1 mutation. Co.'s other product is IDHIFA® (enasidenib) for patients with R/R AML and an IDH2 mutation. Co.'s pre-commercial clinical cancer product candidates include: vorasidenib, a brain-penetrant pan-IDH mutant inhibitor; and AG-270, an orally available selective inhibitor of methionine adenosyltransferase 2a. We show 32 historical shares outstanding datapoints in our coverage of AGIO's shares outstanding history.
Understanding the changing numbers of AGIO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AGIO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AGIO by allowing them to research AGIO shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
